Spencer Feldman

Dr. Ian Flinn explains how subcutaneous Lunsumio VELO uses bispecific antibodies for quick, durable treatment in relapsed/refractory follicular lymphoma.

The U.S. FDA has accepted a supplemental application for Besremi in adults with essential thrombocythemia with an Aug. 30, 2026 action date.

Lung squamous cell carcinoma starts in airway lining cells; treatment depends on stage, from surgery to systemic therapies, with side effects to monitor.

2025 brought key advances in blood cancer treatment, research, and patient insights across multiple myeloma, lymphoma, leukemia and MDS.

The FDA granted orphan drug designation to CK0804, an investigational cell therapy being studied for patients with myelofibrosis.

From kidney to prostate cancer, these 2025 stories highlight research, new treatments and resources helping patients and caregivers stay informed and engaged.

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung cancer care and awareness.

Adding Monjuvi and Revlimid to standard chemotherapy helped patients with newly diagnosed lymphoma live longer without disease worsening.

From hair regrowth to safe pregnancy chemotherapy and new targeted therapies, these top five breast cancer stories of 2025 highlight patient care advances.

Diagnosed with myeloma in 2017, Oya Gilbert highlights self-advocacy, emotional well-being and culturally relevant outreach for underserved patients.

Early trial data suggest Olvi-Vec may shrink or control cancer after platinum therapy, with safety signals in small cell and non-small cell lung cancer.

Your educational guide during a colon cancer diagnosis, including what to expect for screening, staging, treatments and managing side effects.

The FDA approved six new therapies for blood, prostate and lung cancers and supportive care, expanding treatment options based on recent trials.

An expert discusses how precision oncology, immunotherapy, biomarker testing and clinical trials are expanding treatment options for patients with gastric cancer.

Early-phase studies showed INCA033989 led to spleen reduction, symptom improvement and anemia responses in patients with calreticulin-mutated myelofibrosis.

CURE was on site at the 2025 ASH Annual Meeting, sharing expert conversations and patient-focused reporting that highlighted progress in blood cancer care.

Ceralasertib plus Imfinzi failed to improve overall survival versus docetaxel in a phase 3 study of previously treated non-small cell lung cancer.

Integrative oncology combines standard treatment with evidence-based complementary therapies to manage symptoms and empower patients.

The FDA granted accelerated approval to Lunsumio VELO for adults with relapsed/refractory follicular lymphoma after two or more prior treatments.

This patient guide explains triple-positive breast cancer, including treatment options, side effects and more to support informed conversations.

Dan describes how early self-advocacy, second opinions and trial research helped him pursue experimental treatments that led to remission from stage 4 pancreatic cancer.

The FDA granted fast track status to muzastotug plus Keytruda for adults with microsatellite stable metastatic colorectal cancer without liver metastases.

Six-year phase 3 follow-up showed adding Loqtorzi to chemotherapy nearly doubled survival for recurrent or metastatic nasopharyngeal cancer.

The FDA approved Akeega combination therapy for adults with BRCA2-mutated metastatic castration-sensitive prostate cancer.

Real and sham acupuncture improved perceived cognitive function versus usual care, with real acupuncture showing greater benefits for objective cognitive outcomes.

CURE honored four individuals whose compassion and leadership shaped support education and empowerment for people living with blood cancers.

This guide explains how squamous cell lung cancer is diagnosed and treated at each stage to help patients talk openly with their oncology team.

IGV-001 improved survival for newly diagnosed glioblastoma in a phase 2b trial, with patients living a median 20.3 months and no serious safety issues.

Optimism, treatment momentum and communication gaps drive late systemic therapy, increasing hospitalization and intensive care use for patients with cancer.

The FDA approved Armlupeg as a biosimilar to Neulasta to reduce infection risk in people receiving chemotherapy and those exposed to radiation.